Last updated: March 5, 2024
Sponsor: Zeng Changhao
Overall Status: Active - Recruiting
Phase
N/A
Condition
Esophageal Disorders
Achalasia
Treatment
Injectable Type A Botulinum Toxin
Clinical Study ID
NCT06271395
Chaoshengqiunang
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Videofluoroscopic swallowing study (VFSS) confirming incomplete/opening dysfunction ofthe cricopharyngeal muscle;
- No significant improvement in swallowing function after standardized rehabilitationtreatment for more than 2 weeks (unchanged or decreased FOIS);
- Presence of swallowing initiation, with VFSS showing that the upward movement of thehyoid bone during swallowing is greater than half the height of the C3 vertebral body;
- Stable vital signs, alert consciousness, and cooperation with treatment;
Exclusion
Exclusion Criteria:
- Patients with severe cognitive impairments, psychiatric disorders, and severecardiopulmonary diseases;
- Abnormalities in the pharynx and larynx structures;
- Patients with malignant tumors;
- Patients with infections or wounds at the injection site;
- Patients allergic to botulinum toxin; Patients with bleeding tendencies or coagulationdisorders.
Study Design
Total Participants: 30
Treatment Group(s): 1
Primary Treatment: Injectable Type A Botulinum Toxin
Phase:
Study Start date:
February 28, 2024
Estimated Completion Date:
October 31, 2024
Study Description
Connect with a study center
The Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan 450000
ChinaSite Not Available
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan 450000
ChinaSite Not Available
Xinzhu Rehabilitation Hospital
Xinzhu,
TaiwanActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.